ESPEROVAX Trademark
Trademark Overview
On Wednesday, December 20, 2023, a trademark application was filed for ESPEROVAX with the United States Patent and Trademark Office. The USPTO has given the ESPEROVAX trademark a serial number of 98324183. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Tuesday, November 5, 2024. This trademark is owned by Esperovax, Inc.. The ESPEROVAX trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:
Vaccines; Oral vaccines; Modified cells for medical or clinical use; yeast-based pharmaceuticals for prevention or treatment of infectious diseases; Oral vaccine preparations; Pharmaceutical products for the treatment of infectious diseases; Recombinant yeast-based pharmaceutical products for prevention or treatment of infectious diseases; Yeast-based oral vaccines; Pharmaceutical preparations, namely, a drug delivery system for oral administration of vaccines comprising yeast-based oral vaccines; Pharmaceutical products, namely, yeast-based oral vaccines; Biological and pharmaceutical preparations, namely, recombinant yeast for prevention or treatment of infectious diseases
Medical research in the field of vaccines and medicines; Research and development of vaccines and medicines; Research and development in the pharmaceutical and biotechnology fields; Scientific research in the field of vaccines and medicines; Pharmaceutical research and development; Research and development in the field of immunology; Research and development in the field of microorganisms, namely, research and development related to yeast; Research and development in the field of therapeutics; Development of pharmaceutical preparations and medicines; Scientific study and research in the field of medicine; Scientific study and research in the field of healthcare products; Medical and scientific research; Research and development of pharmaceutical and therapeutic preparations; Pharmaceutical, biologic, and vaccine research and development
General Information
| Serial Number | 98324183 |
| Word Mark | ESPEROVAX |
| Filing Date | Wednesday, December 20, 2023 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Tuesday, November 5, 2024 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, November 26, 2024 |
Trademark Statements
| Goods and Services | Vaccines; Oral vaccines; Modified cells for medical or clinical use; yeast-based pharmaceuticals for prevention or treatment of infectious diseases; Oral vaccine preparations; Pharmaceutical products for the treatment of infectious diseases; Recombinant yeast-based pharmaceutical products for prevention or treatment of infectious diseases; Yeast-based oral vaccines; Pharmaceutical preparations, namely, a drug delivery system for oral administration of vaccines comprising yeast-based oral vaccines; Pharmaceutical products, namely, yeast-based oral vaccines; Biological and pharmaceutical preparations, namely, recombinant yeast for prevention or treatment of infectious diseases |
| Goods and Services | Medical research in the field of vaccines and medicines; Research and development of vaccines and medicines; Research and development in the pharmaceutical and biotechnology fields; Scientific research in the field of vaccines and medicines; Pharmaceutical research and development; Research and development in the field of immunology; Research and development in the field of microorganisms, namely, research and development related to yeast; Research and development in the field of therapeutics; Development of pharmaceutical preparations and medicines; Scientific study and research in the field of medicine; Scientific study and research in the field of healthcare products; Medical and scientific research; Research and development of pharmaceutical and therapeutic preparations; Pharmaceutical, biologic, and vaccine research and development |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, December 20, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, December 20, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Esperovax, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Plymouth, MI 48170 |
Trademark Events
| Event Date | Event Description |
| Wednesday, December 20, 2023 | NEW APPLICATION ENTERED |
| Monday, April 1, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Tuesday, July 23, 2024 | NON-FINAL ACTION E-MAILED |
| Wednesday, October 23, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, October 23, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, October 23, 2024 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, October 30, 2024 | EXAMINERS AMENDMENT -WRITTEN |
| Wednesday, October 30, 2024 | EXAMINERS AMENDMENT E-MAILED |
| Wednesday, October 30, 2024 | EXAMINER'S AMENDMENT ENTERED |
| Wednesday, October 30, 2024 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Wednesday, October 30, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, November 20, 2024 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, July 23, 2024 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, July 22, 2024 | ASSIGNED TO EXAMINER |
| Tuesday, July 23, 2024 | NON-FINAL ACTION WRITTEN |
